23 September 2022
Latham & Watkins Advises Spectrum Pharmaceuticals in Debt Financing Agreement With SLR Capital Partners
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | finance | Bay Area |
| Benjamin Gelfand | Latham & Watkins LLP | Associate | finance | Houston |
| Whitley Johnson | Latham & Watkins LLP | Associate | finance | Houston |
| Teri O'Brien | Latham & Watkins LLP | Partner | corporate | San Diego |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | corporate | New York |
| Eric Rice | Latham & Watkins LLP | Associate | corporate | New York |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Los Angeles |
| Ben Haas | Latham & Watkins LLP | Partner | FDA regulatory | Washington, D.C. |
| Meryl Bartlett | Latham & Watkins LLP | Associate | FDA regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Counsel | healthcare regulatory | Bay Area |
Stated terms
- Stated value
- USD 65m (US$65 million)
- What the figure measures
- Facility amount
- Client
- Spectrum Pharmaceuticals, Inc.Borrower
- Counterparties
- SLR Capital Partners, LLC (Lenders)